Day 3: Top Takeaways From ASCO26
Dr. Monty Pal shares highlights from Day 3 of the 2026 ASCO Annual Meeting, including new research for the treatment of advanced CRC and mCRPC, TIL cell therapy in advanced non-uveal melanoma, and an ultra-low dose immunotherapy trial in head and neck squamous cell carcinoma.
LINK TO FULL TRANSCRIPT
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.